Metabolic effects of antidiabetic drugs on adipocytes and adipokine expression

Yaribeygi, Habib; Simental‐Mendía, Luis E.; Barreto, George E.; Sahebkar, Amirhossein

doi:10.1002/jcp.28420

Cited by 24 publications

(18 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we could not confirm that the increased adiponectin concentrations within the first 24 h of a stroke represent a “response” of the human organism. Furthermore, adiponectin levels can be influenced by antidiabetic drugs [50, 51]. However, in this study, serum levels of adiponectin were not influenced by antidiabetic drugs.…”

Section: Discussionmentioning

confidence: 54%

The association between serum adiponectin and 3-month outcome after ischemic stroke

Wang

et al. 2019

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background: Although adiponectin is a major adipocytokine that affects the pathogenesis of various cardiovascular diseases, its clinical significance in stroke remains controversial. The purpose of this study was to assess the impact of serum adiponectin levels on functional prognosis in patients with ischemic stroke. Methods:This was a prospective, observational cohort study. Consecutive first-ever ischemic stroke patients without any pre-morbid handicap admitted to our hospital were identified from December 2017 to December 2018. Serum concentration of adiponectin was routinely measured within the first 24 h after admission by a commercially available sandwich ELISA. Associations between adiponectin and either clinical severity at admission, poor outcomes or mortality at 3-month after admission were analyzed using logistic regression to obtain odds ratios (OR) and 95% confidence intervals (CI). Results:The serum level of adiponectin was obtained in 227 patients with a median value of 7.0 μg/ml, which was significantly higher (P < 0.001) than in those heathy control. Adiponectin levels were associated with moderate-tohigh stroke, and risk increased by 12% (OR = 1.12; 95% CI 1.03-1.25; P = 0.002). Patients with a poor outcome and nonsurvivors had significantly increased adiponectin levels on admission (P < 0.001, all). In multivariate logistic regression analysis, adiponectin was an independent predictor of functional outcome and mortality, and risk increased by 24% (OR = 1.24, 95% CI 1.13-1.37; P < 0.001) and 31% (1.31 [1.18-1.46], P < 0.001), respectively. Kaplan-Meier analysis suggested that the patients with high serum adiponectin levels had a higher risk of death than those patients with low levels (log-rank test P < 0.001). Conclusions:Our results show that high adiponectin is associated with stroke severity and support the hypothesis that adiponectin can be serve as a biomarker of poor outcome after stroke, independent of baseline variables.

show abstract

Section: Discussionmentioning

confidence: 54%

The association between serum adiponectin and 3-month outcome after ischemic stroke

Wang

et al. 2019

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

“…It has demonstrated that adipokine modulators are beneficial in the management of diabetic nephropathy (Yaribeygi et al , 2019c). For example, omentin-1, an adipokine modulator, has shown to have great potential in the amelioration of diabetic nephropathy (Song et al , 2018).…”

Section: Mir-27amentioning

confidence: 99%

MicroRNA-mediated regulation of Nrf2 signaling pathway: Implications in disease therapy and protection against oxidative stress

et al. 2020

Self Cite

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…When glycemia decreases, the opposite is observed [24,26]. Since lipids serve as a substrate for glucose production, DM, obesity and other metabolic conditions are straightly correlated, thus explaining why metabolic syndrome is inevitably increasing among humans [27][28][29][30].…”

Section: Pathophysiology Of T2dmmentioning

confidence: 99%

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I

et al. 2019

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.

show abstract

Metabolic effects of antidiabetic drugs on adipocytes and adipokine expression

Cited by 24 publications

References 133 publications

The association between serum adiponectin and 3-month outcome after ischemic stroke

The association between serum adiponectin and 3-month outcome after ischemic stroke

MicroRNA-mediated regulation of Nrf2 signaling pathway: Implications in disease therapy and protection against oxidative stress

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I

Contact Info

Product

Resources

About